This review examines the current evidence on imaging biomarkers and complementary diagnostic techniques used for patient selection, treatment monitoring, and response assessment in [177Lu]Lu-PSMA-617 therapy for metastatic castrate resistant prostate cancer. The gene discussed is FOLH1; the disease is prostate cancer.